These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dipyridamole--evaluation of an established antithrombotic drug in view of modern concepts of blood cell-vessel wall interactions. Eisert WG; Müller TH Thromb Res Suppl; 1990; 12():65-72. PubMed ID: 2082490 [TBL] [Abstract][Full Text] [Related]
8. Letter: Clinical and experimental effects of dipyridamole. Coeugniet E Thromb Res; 1975 Jul; 7(1):251-2. PubMed ID: 807988 [No Abstract] [Full Text] [Related]
9. [Persantin: coronary insufficiency, prevention of thrombosis, kidney failure, intrauterine asphyxia]. Heynen U Z Allgemeinmed; 1972 Feb; 48(5):246-50. PubMed ID: 5063268 [No Abstract] [Full Text] [Related]
10. [The antithrombotic effect of dipyridamole and acetylsalicylic acid. A prospective clinical examination]. Harjola PT; Meurala H Med Welt; 1981 Jul; 32(30-31):1178. PubMed ID: 7024707 [No Abstract] [Full Text] [Related]
11. Factor Xa is a superior target to factor IIa for antithrombotic therapies. Büller HR Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():37. PubMed ID: 14730477 [No Abstract] [Full Text] [Related]
12. Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. Turpie AG Prog Clin Biol Res; 1982; 89():31-62. PubMed ID: 7051035 [TBL] [Abstract][Full Text] [Related]
13. Studies on the site of action of persantin, segontin and trimanyl. Their effect on the bioelectric activity of rabbit's brain. Janicki K; Trabka J; Gatarski J Pol Med J; 1970; 9(1):1816. PubMed ID: 5437035 [No Abstract] [Full Text] [Related]
14. [Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses]. Iturbe T; Sánchez C; Moreno JA; Olave T; Azaceta G; Varo MJ; Civeira E; Peleato J; Cornudella R Sangre (Barc); 1997 Oct; 42(5):387-90. PubMed ID: 9424739 [TBL] [Abstract][Full Text] [Related]
15. Dipyridamole as an antithrombotic drug. Loeliger EA N Engl J Med; 1988 Oct; 319(14):951-2. PubMed ID: 3419462 [No Abstract] [Full Text] [Related]
16. [Prophylaxis of thrombogenesis in the diabetic patient]. Zurro Hernández J; Arribas Castrillo JM; Durán García S; Quintero de Juana A; Romero E Rev Clin Esp; 1974 Sep; 134(5):473-7. PubMed ID: 4438743 [No Abstract] [Full Text] [Related]
17. In vivo study of bleeding and antithrombotic effects of low molecular weight heparin ML-009723. Malinowska K; Iqbal O; Hoppensteadt DA; Walenga JM; Fareed J Semin Thromb Hemost; 1993; 19 Suppl 1():58-62. PubMed ID: 8395732 [No Abstract] [Full Text] [Related]
18. [Hyperaggregation effects of thrombolytic enzymes]. Brochier M; Griguer P Therapeutique; 1973 Nov; 49(9):565-6. PubMed ID: 4792901 [No Abstract] [Full Text] [Related]
19. The role of endothelium in antithrombotic effect of the renin-angiotensin system blockade. Buczko W; Matys T; Kucharewicz I; Chabielska E J Physiol Pharmacol; 1999 Dec; 50(4):499-507. PubMed ID: 10639001 [TBL] [Abstract][Full Text] [Related]
20. [Hemodynamic effects of dipyridamole (Persantin) following beta-blockade in coronary failure]. Kinsbergen M; Friedemann M Schweiz Med Wochenschr; 1973 Feb; 103(8):312-5. PubMed ID: 4144418 [No Abstract] [Full Text] [Related] [Next] [New Search]